<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Hematol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Exp Hematol Oncol</journal-id><journal-title-group><journal-title>Experimental Hematology &#x00026; Oncology</journal-title></journal-title-group><issn pub-type="epub">2162-3619</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11681632</article-id><article-id pub-id-type="publisher-id">586</article-id><article-id pub-id-type="doi">10.1186/s40164-024-00586-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>AOH1996 targets mitochondrial dynamics and metabolism in leukemic stem cells via mitochondrial PCNA inhibition</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kang</surname><given-names>HyunJun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Valerio</surname><given-names>Melissa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Feng</surname><given-names>Jia</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Long</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hoang</surname><given-names>Dinh Hoa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Blackmon</surname><given-names>Amanda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sharkas</surname><given-names>Shawn</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pathak</surname><given-names>Khyatiben</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Jossart</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhuo</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Hongyu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pirrotte</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Perry</surname><given-names>J. Jefferson P.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hickey</surname><given-names>Robert J.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Malkas</surname><given-names>Linda</given-names></name><address><email>lmalkas@coh.org</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Marcucci</surname><given-names>Guido</given-names></name><address><email>gmarcucci@coh.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nguyen</surname><given-names>Le Xuan Truong</given-names></name><address><email>lenguyen@coh.org</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05fazth07</institution-id><institution-id institution-id-type="ISNI">0000 0004 0389 7968</institution-id><institution>Department of Hematologic Malignancies Translational Science, </institution><institution>Beckman Research Institute and City of Hope National Medical Center, </institution></institution-wrap>Duarte, CA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03kkjyb15</institution-id><institution-id institution-id-type="GRID">grid.440601.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0578</institution-id><institution>Department of Hematology, </institution><institution>Peking University Shenzhen Hospital, </institution></institution-wrap>Shenzhen, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05fazth07</institution-id><institution-id institution-id-type="ISNI">0000 0004 0389 7968</institution-id><institution>Department of Molecular Diagnostics &#x00026; Experimental Therapeutics, </institution><institution>Beckman Research Institute of City of Hope, </institution></institution-wrap>Duarte, CA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02hfpnk21</institution-id><institution-id institution-id-type="GRID">grid.250942.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0507 3225</institution-id><institution>Early Detection and Prevention Division, </institution><institution>Translational Genomics Research Institute, </institution></institution-wrap>Phoenix, AZ USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00w6g5w60</institution-id><institution-id institution-id-type="GRID">grid.410425.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0421 8357</institution-id><institution>Beckman Research Institute, </institution><institution>City of Hope National Medical Center, </institution></institution-wrap>Duarte, CA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00w6g5w60</institution-id><institution-id institution-id-type="GRID">grid.410425.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0421 8357</institution-id><institution>Department of Molecular Medicine, </institution><institution>City of Hope National Medical Center, </institution></institution-wrap>Duarte, CA USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00w6g5w60</institution-id><institution-id institution-id-type="GRID">grid.410425.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 0421 8357</institution-id><institution>City of Hope, </institution></institution-wrap>Duarte, CA 91010 USA </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>13</volume><elocation-id>123</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Cytoplasmic proliferating cell nuclear antigen (PCNA) is highly expressed in acute myeloid leukemia (AML) cells, supporting oxidative metabolism and leukemia stem cell (LSC) growth. We report on AOH1996 (AOH), an oral compound targeting cancer-associated PCNA, which shows significant antileukemic activity. AOH inhibited growth in AML cell lines and primary CD34&#x02009;+&#x02009;CD38&#x02009;&#x02212;&#x02009;blasts (LSC-enriched) in vitro while sparing normal hematopoietic stem cells (HSCs). In vivo, AOH-treated mice demonstrated prolonged survival compared to controls (50 vs. 35 days; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001) with reduced LSC burden, as shown in secondary transplants (42 vs. 30 days, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). Mechanistically, AOH disrupted mitochondrial PCNA&#x02019;s binding to the OPA1 protein, enhancing OPA1&#x02019;s interaction with its E3 ligase, MARCH5, which led to OPA1 degradation. This process reduced mitochondrial length, fatty acid oxidation (FAO), and oxidative phosphorylation (OXPHOS), thereby inhibiting LSC expansion. The addition of venetoclax (VEN), an FDA-approved Bcl-2 inhibitor, further enhanced AOH&#x02019;s effects, reducing mitochondrial length, FAO, and OXPHOS while improving survival in AML models. While VEN is approved for AML, AOH is under clinical investigation for solid tumors, and our findings support its broader therapeutic potential.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s40164-024-00586-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>AOH1996</kwd><kwd>PCNA inhibitor</kwd><kwd>Mitochondrial metabolism</kwd><kwd>Leukemic stem cells</kwd><kwd>AML</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id><award-id>P30CA33572</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>IDDV COH</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; YUMED Inc. and BioMed Central Ltd. 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>To the Editor,</title><p id="Par2">Proliferating cell nuclear antigen (PCNA) is involved in tumor DNA synthesis and repair, and disease progression [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In contrast to its nuclear role, cytoplasmic PCNA maintains mitochondrial DNA integrity, regulates mitochondrial dynamics (such as fission and fusion), and mediates cellular stress responses by supporting mitochondrial function under stress conditions [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. In acute myeloid leukemia (AML), cytoplasmic PCNA is highly expressed, supporting oxidative metabolism and growth, especially in leukemia stem cells (LSCs) [<xref ref-type="bibr" rid="CR5">5</xref>]. LSCs reportedly rely on mitochondrial fusion, fatty acid oxidation (FAO), and oxidative phosphorylation (OXPHOS) for survival [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, targeting cytoplasmic PCNA could disrupt LSC homeostasis, leading to their elimination and potential disease eradication. Building on the previous PCNA inhibitor AOH1160, we developed a leading clinical candidate AOH1996, which is orally administrable and metabolically stable and showed significant inhibition of tumor growth with minimal toxicity for healthy cells [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par3">AOH treatment, significantly inhibited proliferation, colony formation, and induced apoptosis at 24&#x000a0;h in a dose-dependent manner, in seven representative AML cell lines and primary CD34&#x02009;+&#x02009;CD38- blasts (enriched for LSCs), while sparing normal CD34&#x02009;+&#x02009;CD38- mononuclear cells (MNCs) [enriched for hematopoietic stem cells (HSCs)] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A-B and Sup. Figure <xref rid="MOESM1" ref-type="media">S1</xref>). Untargeted metabolomic analysis identified 198 and 213 differentially abundant metabolites in AOH-treated (0.5 &#x000b5;M) primary CD34&#x02009;+&#x02009;AML cells versus DMSO-treated or untreated controls (Adj. <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, Sup. Figure <xref rid="MOESM2" ref-type="media">S2</xref>A and Sup. Table <xref rid="MOESM1" ref-type="media">S1</xref>). To this end, AOH treatment led to reduced NAD+, FAD, and ATP levels, indicating decreased OXPHOS. Additionally, phospholipids, long-chain fatty acids, and acyl carnitines increased, while acetyl carnitine decreased, suggesting increased phospholipid synthesis and reduced FAO (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C and Sup. Table <xref rid="MOESM1" ref-type="media">S1</xref>) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Utilizing Seahorse and FAO functional assays, we confirmed that AOH treatment decreased FAO and OXPHOS (lower OCR) in CD34&#x02009;+&#x02009;CD38- AML blasts (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D and Sup. Figure <xref rid="MOESM2" ref-type="media">S2</xref>B). Transmission electron microscope revealed AOH (1 &#x000b5;M) significantly reduced mitochondrial length (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>E-F), suggesting a potential inhibition of mitofusion. AOH treatment for 24&#x000a0;h also reduced levels of mitofusion-regulated proteins (e.g., OPA1, MFN1) and FAO/OXPHOS-regulated proteins (e.g., BCL-2, CPT1B, NRF2) in HL-60 cells and CD34&#x02009;+&#x02009;CD38- AML blasts (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>G and Sup. Figure <xref rid="MOESM3" ref-type="media">S3</xref>A). PCNA contains an AlkB homolog 2 PCNA-interacting motif (APIM), which binds to OPA1. Treatment with AOH disrupted the APIM -mediated OPA1- mitochondrial PCNA binding (Sup. Figure <xref rid="MOESM3" ref-type="media">S3</xref>B-C), which led to increased OPA1 binding to its E3 ligase, MARCH5, and ubiquitination and accelerates degradation of this protein (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>H-J and Sup. Figure <xref rid="MOESM3" ref-type="media">S3</xref>D). Thus, these results suggest that AOH inhibits mitofusion and mitochondrial oxidative metabolisms in LSC-enriched blast subpopulation by targeting cytoplasmic PCNA [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par4">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Impact of AOH1996 (AOH) on leukemic stem cells and leukemogenesis via inhibition of mitofusion and mitochondrial metabolism. <bold>A</bold> Effects of AOH (1 &#x000b5;M) on proliferation and apoptosis of LSC-enriched AML blasts. CD34&#x02009;+&#x02009;CD38- cells were isolated from primary MNCs (<italic>n</italic>&#x02009;=&#x02009;4) or AML blasts (<italic>n</italic>&#x02009;=&#x02009;4). Top, cell proliferation levels. Bottom, apoptosis levels. <bold>B</bold> Effects of AOH on colony formation of LSC-enriched AML blasts. CD34&#x02009;+&#x02009;CD38- AML blasts (top) or MNCs (bottom) (2&#x02009;&#x000d7;&#x02009;10&#x02075; cells/mL, <italic>n</italic>&#x02009;=&#x02009;3) were treated with DMSO control (CON) or indicated doses of AOH for 24&#x000a0;h, then plated in methylcellulose. After 14 days, colonies were imaged using a light microscope and counted. Data are shown as mean&#x02009;&#x000b1;&#x02009;SE, with triplicate determinations. <bold>C</bold> Unsupervised hierarchical clustering of significantly different (adj. <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) metabolites from primary CD34&#x02009;+&#x02009;AML blasts treated with AOH (0.5 &#x000b5;M), DMSO or Non-treat controls for 24&#x000a0;h. Metabolite changes were displayed as a heat map. <bold>D-F</bold> Primary CD34&#x02009;+&#x02009;CD38- AML blasts were treated with VEH or AOH (1 &#x000b5;M) for 24&#x000a0;h. <bold>D</bold> Effects of AOH on FAO (measured by &#x000b3;H-palmitate levels, top) and OXPHOS (indicated by OCR levels, bottom), with the OCR comparison focused on maximal respiratory capacity. <bold>E</bold> Transmission electron microscopy (TEM) imaging of mitochondria. Enlarged images are shown. Scale bar, 1&#x000a0;&#x003bc;m. <bold>F</bold> Quantification of mitochondrial length (<italic>n</italic>&#x02009;=&#x02009;30). Asterisks indicate statistically significant differences based on unpaired t-test analysis. <bold>G-J</bold> AOH effects on mitochondrial PCNA&#x02019;s interaction with OPA1 and its impact on OPA1 stability in CD34&#x02009;+&#x02009;CD38- AML blasts treated with VEH or AOH (1 &#x000b5;M) for 24&#x000a0;h. <bold>G</bold> Immunoblot analysis of mitofusion-regulated and mitochondrial metabolism-regulated proteins. <bold>H</bold> Mitochondrial fractions from treated cells were immunoprecipitated with anti-PCNA and immunoblotted with anti-OPA1 antibodies. Input loading controls are shown. <bold>I</bold> Cells were treated with cycloheximide, a translation inhibitor, (CHX, 10 &#x000b5;M), to assess protein stability, for indicated times, and lysates were immunoblotted with anti-OPA1 antibodies. <bold>J</bold> Left, lysates were immunoprecipitated with anti-OPA1 and immunoblotted with anti-MARCH5 antibodies. Input loading controls are shown. Right, ubiquitination assay with lysates immunoprecipitated with anti-OPA1 and immunoblotted with anti-Ub antibodies. <bold>K-L</bold> Antileukemic activities of AOH in vivo. Human primary AML blasts (1.0&#x02009;&#x000d7;&#x02009;10&#x02076;) were injected intravenously into Es1(ko) SCID mice. After 7 days, mice were treated with vehicle control or AOH (100&#x000a0;mg/kg, BID, oral gavage, 3 weeks). <bold>K</bold> Leukemia burden at day 17 post-transplant, measured by the percentage of human CD45&#x02009;+&#x02009;cells (left) and spleen size (right). <bold>L</bold> Left, effects of AOH treatment in vivo on FAO/OXPHOS in human CD45&#x02009;+&#x02009;cells isolated from treated mice. FAO (top) and OXPHOS (bottom, indicated by OCR) levels were measured. Right, top Kaplan&#x02013;Meier survival curve of primary transplanted leukemic mice treated with CON (black line, <italic>n</italic>&#x02009;=&#x02009;10) and AOH-treated mice (red line, <italic>n</italic>&#x02009;=&#x02009;10). Median survival (MS): 35 days (CON), 50 days (AOH). Right, bottom, Kaplan&#x02013;Meier survival curve of secondary transplanted leukemic mice treated with CON (black line, <italic>n</italic>&#x02009;=&#x02009;10) and AOH-treated mice (red line, <italic>n</italic>&#x02009;=&#x02009;10). MS: 30 days (CON), 42 days (AOH). Statistical significance determined by Log-rank (Mantel&#x02013;Cox) test (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001)</p></caption><graphic xlink:href="40164_2024_586_Fig1_HTML" id="d33e552"/></fig>
</p><p id="Par5">In vivo, we demonstrated a significant antileukemic activity of AOH in AML PDXs. Compared to vehicle-treated mice, PDX mice receiving AOH (100&#x000a0;mg/kg, BID, 3 weeks) showed reduced leukemia burden (percentage of hCD45&#x02009;+&#x02009;in peripheral blood and spleen size) and extended median survival (CON: 35 days vs. AOH: 50 days) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>K-L). Analysis of human CD34&#x02009;+&#x02009;cells from the bone marrow of treated mice, showed decreased FAO/OXPHOS levels (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>L, <bold>left</bold>). The antileukemic effect decreased LSC burden, as evidenced by the longer survival of recipients of BM MNCs from AOH-treated donors compared with recipients of BM MNCs from vehicle-treated donors in subsequent transplants (CON: 30 days vs. AOH: 42 days) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>L, <bold>right bottom</bold>). Of note, AOH in combination with a BCL-2 inhibitor, venetoclax (VEN), resulted in a synergistic activity in vitro, as shown by inhibition of FAO/OXPHOS, reduction in mitochondria length, and increased apoptosis of CD34&#x02009;+&#x02009;CD38- AML blasts (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A-E). The AOH/VEN combination significantly extended survival in both primary and secondary transplant experiments in murine (Mll<sup>PTD/WT</sup>/Flt3<sup>ITD/ITD</sup>) [<xref ref-type="bibr" rid="CR12">12</xref>] models compared to either agent alone. Primary survival (days): CON: 34, VEN: 34, AOH: 43.5, AOH/VEN: 54; secondary survival (days): CON: 28, VEN: 32.5, AOH: 41, AOH/VEN: 49.5 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F-G and Sup. Figure <xref rid="MOESM4" ref-type="media">S4</xref>A-B). Similar results were seen in PDX AML models (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>H-I). Notably, the drug treatment did not affect mouse weight (Sup. Figure <xref rid="MOESM4" ref-type="media">S4</xref>C).</p><p id="Par6">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Synergistic effects of AOH and VEN in vitro and in vivo. <bold>A</bold> Synergistic effect of AOH and VEN on LSC-enriched AML blasts. Two primary CD34&#x02009;+&#x02009;CD38- AML samples were used: AML sample-1 (corresponding to AML-2 in Table <xref rid="MOESM2" ref-type="media">S2</xref>) and AML-sample 2 (corresponding to AML-3 in Table <xref rid="MOESM2" ref-type="media">S2</xref>). Cells (1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL, <italic>n</italic>&#x02009;=&#x02009;3) were treated with indicated concentration of AOH and VEN. Levels of cell proliferation were evaluated and synergy score of the drug combination was calculated. Maximum synergy scores were 26.32 for AML sample-1 and 22.98 for AML sample-2. <bold>B-D</bold> Combinatorial effects of AOH and VEN on FAO/OXPHOS levels and mitochondrial length of LSC-enriched AML blasts. Primary CD34&#x02009;+&#x02009;CD38- AML blasts (<italic>n</italic>&#x02009;=&#x02009;4) were treated with DMSO (CON), AOH (1 &#x000b5;M), VEN (20 nM), or combination of AOH and VEN for 24&#x000a0;h. <bold>B</bold> FAO levels. <bold>C</bold> OXPHOS levels (indicated by OCR), with OCR comparisons focused on maximal respiratory capacity. <bold>D</bold> Mitochondria length. Left, represented TEM images. Right, quantification of mitochondria length (<italic>n</italic>&#x02009;=&#x02009;30). <bold>E</bold> Primary CD34&#x02009;+&#x02009;CD38- AML blasts (<italic>n</italic>&#x02009;=&#x02009;4) were treated with DMSO (CON), VEN (20 nM), AOH (1 &#x000b5;M), or combination of AOH and VEN for 24&#x000a0;h. Top, DNA fragmentation. Bottom, PARP cleavage. ANOVA test was performed for multiple group comparisons prior to statistical analysis of each two group comparisons. <bold>F-G</bold> Combinatorial effects of AOH and VEN on Mll<sup>PTD/WT</sup>/Flt3<sup>ITD/ITD</sup> AML mouse model. Kaplan-Meier curve employing log-rank test was used to find statistical significance. <bold>F</bold> Experimental design for AOH and VEN combined treatment. 1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> Mll<sup>PTD/WT</sup>/Flt3<sup>ITD/ITD</sup> BM MNCs were intravenously injected into normal Ces1c(ko) B6 WT recipients. The transplanted mice were then randomly divided into 4 groups 7 days post-transplant (<italic>n</italic>&#x02009;=&#x02009;10/group) and treated with either vehicle (CON), AOH (100&#x000a0;mg/kg, BID, PO, 21 days), VEN (100&#x000a0;mg/kg, daily, PO, 21 days) or AOH/VEN at the same doses of single agents. On day 28 post-transplant, 10<sup>6</sup> BM MNCs cells from each treatment group were harvested for secondary transplant. <bold>G</bold> Left, Kaplan&#x02013;Meier survival curve of primary transplanted leukemic mice treated with CON (black line, MS 34 days), VEN (blue line, MS 34 days), AOH (red line, MS 43.5 days), or AOH/VEN (purple line, MS 54 days). Right, Kaplan&#x02013;Meier survival curve of secondary transplanted leukemic mice treated with CON (black line, MS 28 days), VEN (blue line, MS 32.5 days), AOH (red line, MS 41 days), or AOH/VEN (purple line, MS 49.5 days). <bold>H-I</bold> Combinatorial effects of AOH and VEN on FLT3-WT PDX AML model. <bold>H</bold> Experimental design for AOH and VEN combined treatment. hCD45&#x02009;+&#x02009;BM FLT3-WT AML cells (1&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells/mouse) were transplanted into Es1(ko) SCID mice to generate a cohort of AML bearing PDX mice. The transplanted mice were then randomly divided into 4 groups 7 days post-transplant (<italic>n</italic>&#x02009;=&#x02009;10/group) and treated with either vehicle (CON), AOH (100&#x000a0;mg/kg, BID, PO, 21 days), VEN (100&#x000a0;mg/kg, daily, PO, 21 days) or AOH/VEN at the same doses of single agents. On day 28, 10<sup>6</sup> BM MNCs cells from each treatment group were harvested for secondary transplant. <bold>I</bold> Left, Kaplan&#x02013;Meier survival curve of primary transplanted leukemic mice treated with CON [black line, median survival (MS) 41 days], VEN (blue line, MS 48 days), AOH (red line, MS 55 days), or AOH/VEN (purple line, MS 75.5 days). Right, Kaplan&#x02013;Meier survival curve of secondary transplanted leukemic mice treated with CON (black line, MS 40 days), VEN (blue line, MS 51 days), AOH (red line, MS 60 days), or AOH/VEN (purple line, MS 76 days)</p></caption><graphic xlink:href="40164_2024_586_Fig2_HTML" id="d33e687"/></fig>
</p><p id="Par7">In summary, AOH exhibits potent antileukemic activity in AML models by inhibiting mitochondrial PCNA-regulated dynamics and metabolism and reducing LSC burden. Of note, we also observed enhanced activity when AOH is combined with VEN. While VEN is FDA-approved for AML, AOH is a novel compound currently in clinical trials for solid tumors and undergoing IND-enabling studies for leukemia.</p></sec><sec id="Sec2" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="40164_2024_586_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="40164_2024_586_MOESM2_ESM.tif"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="40164_2024_586_MOESM3_ESM.tif"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="40164_2024_586_MOESM4_ESM.tif"><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="40164_2024_586_MOESM5_ESM.tif"><caption><p>Supplementary Material 5</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="40164_2024_586_MOESM6_ESM.xlsx"><caption><p>Supplementary Material 6</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>HyunJun Kang, Melissa Valerio and Jia Feng contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank the Animal Resources Center and the various core facilities - including Analytical Cytometry, Light Microscopy, Electron Microscopy, and Integrated Mass Spectrometry Shared Resource Cores - at the City of Hope Comprehensive Cancer Center for their invaluable support. This support is made possible by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. Our heartfelt appreciation also goes out to the City of Hope Comprehensive Cancer Center, the patients, and their physicians for providing the essential materials for this study. This study was supported by the Integrated Drug Development Venture (IDDV) program, City of Hope&#x02019;s unique internal funding mechanism of selected scientific discoveries, enabling preclinical and clinical development to speedily advance products toward commercialization, such as AOH-1996.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>H.K., M.V., J.F., L.G., D.H.H., A.B., S.S., K.P., J.J., and Z.L. conducted experiments; H.Z., B.Z., P.P., J.P.P., and R.J.H. reviewed data and the manuscript; L.M. provided AOH1996; L.X.T.N., and G.M. designed experiments, analyzed data, wrote manuscript and provided administrative support. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Integrated Drug Development Venture (IDDV) program at City of Hope and partially supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par10">Healthy donor-derived normal hematopoietic stem cells (HSCs) and acute myeloid leukemia (AML) specimens were sourced from the City of Hope National Medical Center (COHNMC) in accordance with approved banking protocols (#06229, #03162, #07047, or #18067) sanctioned by the City of Hope Institutional Review Board. These protocols adhere to the guidelines set forth by the Department of Health and Human Services and are compliant with the principles outlined in the Declaration of Helsinki. Prior to specimen acquisition, written informed consent was obtained from donors (#06229) or patients (#03162, #07047, or #18067).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par8">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par9">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Strzalka</surname><given-names>W</given-names></name><name><surname>Ziemienowicz</surname><given-names>A</given-names></name></person-group><article-title>Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation</article-title><source>Ann Bot</source><year>2011</year><volume>107</volume><issue>7</issue><fpage>1127</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/aob/mcq243</pub-id><pub-id pub-id-type="pmid">21169293</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Strzalka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot. 2011;107(7):1127&#x02013;40.<pub-id pub-id-type="pmid">21169293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Proliferating cell nuclear antigen promotes cell proliferation and tumorigenesis by up-regulating STAT3 in non-small cell lung cancer</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>104</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.05.071</pub-id><pub-id pub-id-type="pmid">29803172</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Wang L, Kong W, Liu B, Zhang X. Proliferating cell nuclear antigen promotes cell proliferation and tumorigenesis by up-regulating STAT3 in non-small cell lung cancer. Biomed Pharmacother. 2018;104:595&#x02013;602.<pub-id pub-id-type="pmid">29803172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Naryzhny</surname><given-names>SN</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer</article-title><source>FEBS Lett</source><year>2010</year><volume>584</volume><issue>20</issue><fpage>4292</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2010.09.021</pub-id><pub-id pub-id-type="pmid">20849852</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Naryzhny SN, Lee H. Proliferating cell nuclear antigen in the cytoplasm interacts with components of glycolysis and cancer. FEBS Lett. 2010;584(20):4292&#x02013;8.<pub-id pub-id-type="pmid">20849852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000f8;st</surname><given-names>LM</given-names></name><name><surname>R&#x000e6;der</surname><given-names>SB</given-names></name><name><surname>Olaisen</surname><given-names>C</given-names></name><etal/></person-group><article-title>PCNA regulates primary metabolism by scaffolding metabolic enzymes</article-title><source>Oncogene</source><year>2023</year><volume>42</volume><issue>8</issue><fpage>613</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41388-022-02579-1</pub-id><pub-id pub-id-type="pmid">36564470</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">R&#x000f8;st LM, R&#x000e6;der SB, Olaisen C, et al. PCNA regulates primary metabolism by scaffolding metabolic enzymes. Oncogene. 2023;42(8):613&#x02013;24.<pub-id pub-id-type="pmid">36564470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Ohayon</surname><given-names>D</given-names></name><name><surname>De Chiara</surname><given-names>A</given-names></name><name><surname>Chapuis</surname><given-names>N</given-names></name><etal/></person-group><article-title>Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><issue>1</issue><fpage>35561</fpage><pub-id pub-id-type="doi">10.1038/srep35561</pub-id><pub-id pub-id-type="pmid">27759041</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ohayon D, De Chiara A, Chapuis N, et al. Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia. Sci Rep. 2016;6(1):35561.<pub-id pub-id-type="pmid">27759041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>de Beauchamp</surname><given-names>L</given-names></name><name><surname>Himonas</surname><given-names>E</given-names></name><name><surname>Helgason</surname><given-names>GV</given-names></name></person-group><article-title>Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia</article-title><source>Leukemia</source><year>2022</year><volume>36</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41375-021-01416-w</pub-id><pub-id pub-id-type="pmid">34561557</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36(1):1&#x02013;12.<pub-id pub-id-type="pmid">34561557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Lagadinou</surname><given-names>ED</given-names></name><name><surname>Sach</surname><given-names>A</given-names></name><name><surname>Callahan</surname><given-names>K</given-names></name><etal/></person-group><article-title>BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells</article-title><source>Cell Stem Cell</source><year>2013</year><volume>12</volume><issue>3</issue><fpage>329</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.12.013</pub-id><pub-id pub-id-type="pmid">23333149</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329&#x02013;41.<pub-id pub-id-type="pmid">23333149</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Small molecule targeting of transcription-replication conflict for selective chemotherapy</article-title><source>Cell Chem Biol</source><year>2023</year><volume>30</volume><issue>10</issue><fpage>1235</fpage><lpage>e12471236</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2023.07.001</pub-id><pub-id pub-id-type="pmid">37531956</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gu L, Li M, Li CM, et al. Small molecule targeting of transcription-replication conflict for selective chemotherapy. Cell Chem Biol. 2023;30(10):1235&#x02013;e12471236.<pub-id pub-id-type="pmid">37531956</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Lingeman</surname><given-names>R</given-names></name><name><surname>Yakushijin</surname><given-names>F</given-names></name><etal/></person-group><article-title>The Anticancer activity of a first-in-class small-molecule Targeting PCNA</article-title><source>Clin Cancer Res</source><year>2018</year><volume>24</volume><issue>23</issue><fpage>6053</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-0592</pub-id><pub-id pub-id-type="pmid">29967249</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Gu L, Lingeman R, Yakushijin F, et al. The Anticancer activity of a first-in-class small-molecule Targeting PCNA. Clin Cancer Res. 2018;24(23):6053&#x02013;65.<pub-id pub-id-type="pmid">29967249</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Seneviratne</surname><given-names>AK</given-names></name><name><surname>Schimmer</surname><given-names>AD</given-names></name></person-group><article-title>Phospholipid metabolism regulates AML growth and stemness</article-title><source>Aging</source><year>2019</year><volume>11</volume><issue>12</issue><fpage>3895</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.18632/aging.102055</pub-id><pub-id pub-id-type="pmid">31237862</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Xu M, Seneviratne AK, Schimmer AD. Phospholipid metabolism regulates AML growth and stemness. Aging. 2019;11(12):3895&#x02013;7.<pub-id pub-id-type="pmid">31237862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tcheng</surname><given-names>M</given-names></name><name><surname>Roma</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><etal/></person-group><article-title>Very long chain fatty acid metabolism is required in acute myeloid leukemia</article-title><source>Blood</source><year>2021</year><volume>137</volume><issue>25</issue><fpage>3518</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1182/blood.2020008551</pub-id><pub-id pub-id-type="pmid">33720355</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tcheng M, Roma A, Ahmed N, et al. Very long chain fatty acid metabolism is required in acute myeloid leukemia. Blood. 2021;137(25):3518&#x02013;32.<pub-id pub-id-type="pmid">33720355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Nguyen</surname><given-names>LXT</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group><article-title>Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><issue>4</issue><fpage>450</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nm.4499</pub-id><pub-id pub-id-type="pmid">29505034</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Zhang B, Nguyen LXT, Li L, et al. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med. 2018;24(4):450&#x02013;62.<pub-id pub-id-type="pmid">29505034</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>